12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Five Prime, Lonza, Kyowa Hakko Kirin deal

Five Prime received rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell line technology to antibodies in Five Prime's cancer pipeline. Potelligent CHOK1SV...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >